151 related articles for article (PubMed ID: 35640328)
1. A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.
Li C; Zhou Y; Xu J; Zhou X; Huang Z; Zeng T; Yang X; Tao L; Gou K; Zhong X; Chen Q; Luo Y; Zhao Y
Eur J Med Chem; 2022 Aug; 238():114489. PubMed ID: 35640328
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment.
Li C; Yang X; Luo Y; Liu H; Zhong X; Zhou X; Zeng T; Tao L; Zhou Y; Gou K; Yang X; Liu X; Chen Q; Zhao Y; Luo Y
J Med Chem; 2021 Dec; 64(24):18175-18192. PubMed ID: 34905371
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold.
Li C; Zhou Y; Xu J; Zhou X; Liu S; Huang Z; Qiu Z; Zeng T; Gou K; Tao L; Zhong X; Yang X; Zhou Y; Su N; Chen Q; Zhao Y; Luo Y
Eur J Med Chem; 2022 Dec; 243():114737. PubMed ID: 36115209
[TBL] [Abstract][Full Text] [Related]
4. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Optimization of Novel
Zhou X; Gou K; Xu J; Jian L; Luo Y; Li C; Guan X; Qiu J; Zou J; Zhang Y; Zhong X; Zeng T; Zhou Y; Xiao Y; Yang X; Chen W; Gao P; Liu C; Zhou Y; Tao L; Liu X; Cen X; Chen Q; Sun Q; Luo Y; Zhao Y
J Med Chem; 2023 Nov; 66(21):14755-14786. PubMed ID: 37870434
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel substituted benzamide derivatives bearing a 1,2,3-triazole moiety as potent human dihydroorotate dehydrogenase inhibitors.
Lu K; Cai L; Zhang X; Wu G; Xu C; Zhao Y; Gong P
Bioorg Chem; 2018 Feb; 76():528-537. PubMed ID: 29316525
[TBL] [Abstract][Full Text] [Related]
8. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022).
Gehlot P; Vyas VK
Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439
[TBL] [Abstract][Full Text] [Related]
9. Discovery a series of novel inhibitors of human dihydroorotate dehydrogenase: Biological activity evaluation and molecular docking.
Ren X; Liu X; Hua M; Dai Y; Ren X; Sui C; Li X; Jiang Z; Tian M; Yang B
Chem Biol Drug Des; 2024 Jan; 103(1):e14388. PubMed ID: 37926553
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and inhibitory activity against human dihydroorotate dehydrogenase (hDHODH) of 1,3-benzoazole derivatives bearing amide units.
Li J; Wu D; Xu X; Huang J; Shao X; Li Z
Bioorg Med Chem Lett; 2016 Jul; 26(13):3064-3066. PubMed ID: 27220723
[TBL] [Abstract][Full Text] [Related]
11. Tiratricol, a thyroid hormone metabolite, has potent inhibitory activity against human dihydroorotate dehydrogenase.
Cao S; Ma H; Xu Z; Fang W; Huang J; Huang Y
Chem Biol Drug Des; 2023 Jul; 102(1):1-13. PubMed ID: 37088711
[TBL] [Abstract][Full Text] [Related]
12. Effect of the Intramolecular Hydrogen Bond on the Active Metabolite Analogs of Leflunomide for Blocking the Plasmodium falciparum Dihydroorotate Dehydrogenase Enzyme: QTAIM, NBO, and Docking Study.
Heidarian R; Zahedi-Tabrizi M
Curr Comput Aided Drug Des; 2021; 17(3):480-491. PubMed ID: 32459610
[TBL] [Abstract][Full Text] [Related]
13. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
Zhang L; Zhang J; Wang J; Ren C; Tang P; Ouyang L; Wang Y
Eur J Med Chem; 2022 Mar; 232():114176. PubMed ID: 35151222
[TBL] [Abstract][Full Text] [Related]
14. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
Jones SW; Penman SL; French NS; Park BK; Chadwick AE
Toxicol In Vitro; 2021 Apr; 72():105096. PubMed ID: 33460737
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
Molecules; 2018 May; 23(6):. PubMed ID: 29794978
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design.
Vyas VK; Qureshi G; Oza D; Patel H; Parmar K; Patel P; Ghate MD
Bioorg Med Chem Lett; 2019 Apr; 29(7):917-922. PubMed ID: 30738663
[TBL] [Abstract][Full Text] [Related]
18. Structural Optimization and Structure-Activity Relationship of 4-Thiazolidinone Derivatives as Novel Inhibitors of Human Dihydroorotate Dehydrogenase.
Zeng F; Quan L; Yang G; Qi T; Zhang L; Li S; Li H; Zhu L; Xu X
Molecules; 2019 Jul; 24(15):. PubMed ID: 31370178
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents.
Vyas VK; Variya B; Ghate MD
Eur J Med Chem; 2014 Jul; 82():385-93. PubMed ID: 24929289
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds.
Sainas S; Pippione AC; Giorgis M; Lupino E; Goyal P; Ramondetti C; Buccinnà B; Piccinini M; Braga RC; Andrade CH; Andersson M; Moritzer AC; Friemann R; Mensa S; Al-Kadaraghi S; Boschi D; Lolli ML
Eur J Med Chem; 2017 Mar; 129():287-302. PubMed ID: 28235702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
